Tempest Therapeutics logo

Tempest TherapeuticsNASDAQ: TPST

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

12 November 2012

Next earnings report:

19 March 2025

Last dividends:

N/A

Next dividends:

N/A
$37.75 M
-73%vs. 3y high
31%vs. sector
-vs. 3y high
-vs. sector
-44%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 00:35:48 GMT
$0.87+$0.04(+4.23%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TPST Latest News

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
globenewswire.com15 August 2024 Sentiment: POSITIVE

BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma (HCC).

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com08 August 2024 Sentiment: POSITIVE

BRISBANE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended June 30, 2024, and provided a corporate update.

Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
investorplace.com20 June 2024 Sentiment: POSITIVE

Tempest Therapeutics (NASDAQ: TPST ) stock is heading higher on Thursday after the clinical-stage oncology company announced plans to show off new study data. Tempest Therapeutics will be holding a conference call at 8:30 a.m.

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch
Seeking Alpha17 April 2024 Sentiment: POSITIVE

Tempest Therapeutics, Inc. saw promising results in a phase 1b/2 study using TPST-1120 in combination with Tecentriq and Avastin for treating first-line HCC patients, with significant improvements in both confirmed and unconfirmed responses. Updated results from the study are anticipated in 2024. The global market for liver cancer drugs is projected to reach $7.6 billion by 2033.

The Secrets Behind a 4000% Biotech Stock Surge
MarketBeat17 October 2023 Sentiment: POSITIVE

Remarkably, the stock did not have fundamentally changing news. It did not rocket higher on breaking news that would typically be associated with the whopping gains it experienced.

Tempest Therapeutics shares end wild week with 8% drop
Market Watch13 October 2023 Sentiment: NEGATIVE

Shares of Tempest Therapeutics Inc. TPST, -8.54% fell more than 8% Friday to conclude a dramatic week in which the stock clocked a one-day gain of nearly 4,000%.

Tempest Therapeutics shares head back to earth after 4,000% gain
Market Watch12 October 2023 Sentiment: NEGATIVE

Shares of microcap oncology company Tempest Therapeutics Inc. TPST, -55.06% dropped more than 50% Thursday as investors took a breath after the stock's roughly 40-fold gain on Wednesday.

Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals
Zacks Investment Research12 October 2023 Sentiment: POSITIVE

Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.

TPST Stock: 7 Things to Know About Tempest Therapeutics
InvestorPlace11 October 2023 Sentiment: POSITIVE

Today, most of Wall Street is watching Tempest Therapeutics (NASDAQ: TPST ). This little-known clinical-stage oncology company has gone from trading at 30 cents per share 24 hours ago to its current share price of $6.40.

Why Is Tempest Therapeutics (TPST) Stock Up 325% Today?
InvestorPlace11 October 2023 Sentiment: POSITIVE

Tempest Therapeutics (NASDAQ: TPST ) stock is taking off on Wednesday as the clinical-stage oncology company prepares to release new study results. According to a press release from the company, it intends to release updated study results from a Phase 1b/2 combination study of TPST-1120 with atezolizumab and bevacizumab.

What type of business is Tempest Therapeutics?

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

What sector is Tempest Therapeutics in?

Tempest Therapeutics is in the Healthcare sector

What industry is Tempest Therapeutics in?

Tempest Therapeutics is in the Biotechnology industry

What country is Tempest Therapeutics from?

Tempest Therapeutics is headquartered in United States

When did Tempest Therapeutics go public?

Tempest Therapeutics initial public offering (IPO) was on 12 November 2012

What is Tempest Therapeutics website?

https://www.tempesttx.com

Is Tempest Therapeutics in the S&P 500?

No, Tempest Therapeutics is not included in the S&P 500 index

Is Tempest Therapeutics in the NASDAQ 100?

No, Tempest Therapeutics is not included in the NASDAQ 100 index

Is Tempest Therapeutics in the Dow Jones?

No, Tempest Therapeutics is not included in the Dow Jones index

When was Tempest Therapeutics the previous earnings report?

No data

When does Tempest Therapeutics earnings report?

The next expected earnings date for Tempest Therapeutics is 19 March 2025